⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL751048 | 0.67 | — | — | |
| SCHEMBL747462 | 0.67 | — | — | |
| SCHEMBL2925272 | 0.67 | — | — | |
| SCHEMBL2750828 | 0.66 | GABRA1 (0.30) | — | |
| SCHEMBL2750653 | 0.66 | NOTUM (0.33) | — | |
| SCHEMBL2047395 | 0.64 | — | — | |
| SCHEMBL17103382 | 0.64 | — | — | |
| SCHEMBL667974 | 0.62 | — | — | |
| SCHEMBL750068 | 0.62 | — | — | |
| SCHEMBL1247212 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034737-A1 | Heterocyclic Derivatives as P2X7 Receptor Antagonists | BREYE THERAPEUTICS APS (DK) | 2024-02-01 | — | — | US | claimed |
| CN-117157291-A | Heterocyclic derivatives as P2X7 receptor antagonists | 布雷耶疗法有限公司 | 2023-12-01 | — | — | CN | claimed |
| EP-4262975-A1 | HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Breye Therapeutics ApS (DK) | 2023-10-25 | — | — | EP | claimed |
| US-11753405-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-12 | — | — | US | claimed |
| WO-2022129365-A1 | HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2022-06-23 | — | — | WO | claimed |
| EP-4015039-A1 | HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | AXXAM S.p.A. (IT) | 2022-06-22 | — | — | EP | claimed |
| CN-108349966-B | 1,3, 4-thiadiazole compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-02-15 | — | — | CN | claimed |
| CN-108349967-B | 1,3, 4-thiadiazole compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-02-15 | — | — | CN | claimed |
| CN-108349965-B | 1,3, 4-thiadiazole compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2021-10-26 | — | — | CN | claimed |
| US-20210246131-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-08-12 | — | — | US | claimed |
| CN-1751025-A | Diamine derivatives | DAIICHI SEIYAKU CO (JP) | 2006-03-22 | — | — | CN | claimed |
| CN-1745071-A | Novel ethylenediamine derivative | DAIICHI SEIYAKU CO (JP) | 2006-03-08 | — | — | CN | claimed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | claimed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | claimed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | claimed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | claimed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | claimed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | claimed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | claimed |
| CN-1348449-A | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH AS (DK) | 2002-05-08 | — | — | CN | claimed |